Thermo Fisher Scientific Depreciation increased by 10.9% to $306.00M in Q1 2026 compared to the prior quarter.
Higher depreciation relative to capital expenditures may suggest aging assets, while lower levels relative to revenue may indicate high asset efficiency.
Depreciation is a non-cash accounting charge that allocates the cost of tangible assets over their useful lives. It refl...
Standardized for capital-intensive industries; peers in manufacturing typically show significant depreciation expenses.
operating_depreciation| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $276.00M | $306.00M |
| QoQ Change | — | +10.9% |
| YoY Change | — | +10.9% |
| Segment | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Laboratory Products and Biopharma Services | — | — | — | — | — | — | $115.00M | $186.00M |
| Life Sciences Solutions | $55.00M | $55.00M | $55.00M | $55.00M | $58.00M | $59.00M | $62.00M | $70.00M |
| Analytical Instruments | $23.25M | $23.25M | $23.25M | $23.25M | $25.00M | $24.00M | $26.00M | $26.00M |
| Specialty Diagnostics | $21.50M | $21.50M | $21.50M | $21.50M | $29.00M | $22.00M | $23.00M | $24.00M |
| Laboratory Productsand Services | $167.25M | $167.25M | $167.25M | — | — | — | — | — |
| Total | — | — | — | — | — | $276.00M | — | $306.00M |
Laboratory Productsand Services is derived from annual filings.
Laboratory Productsand Services was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.